Skip to content
Annika Bansal – Lifestyle
Author:
Septerna, Inc.
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
August 10, 2026
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
May 28, 2026
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
May 22, 2026
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
May 22, 2026
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
May 11, 2026
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
May 5, 2026
Septerna to Present at Bank of America Securities Health Care Conference
May 5, 2026
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
April 29, 2026
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
April 13, 2026
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
April 13, 2026
1
2
Next Page
→